No description available.

Background: Drugs targeting angiogenic pathway remain the mainstay of treatment for metastatic renal cell carcinoma (mRCC). Tyrosine Kinase Inhibitors (TKI) as Sunitinib, Pazopanib as single agents and humanised monoclonal antibody bevacizumab (Bev) in combination with Interferon- α2a (IFN) have established as the first-line therapy for mRCC. Despite improvements in treatment, there are multiple questions which remain unanswered. In the combination of Bev and IFN, the respective role of each drug and whether any additional anti-angiogenic activity is gained by adding IFN to Bev remains unknown. As the clinical benefit obtained with these cytostatic agents does not always correlate with the conventional response assessment techniques as RECIST, it is necessary to reconsider the methods by which we assess benefit from these therapies. In this thesis, I report three studies aiming to answer these questions. Methods: With the clinical trial reported here, I explore whether Bev induced changes in vascular parameters measured by Dynamic Contrast Enhanced MRI (DCE-MRI) is significantly enhanced by the addition of IFN. In a phase II, randomised, open labelled, multicentre trial, treatment naïve mRCC patients were randomised to receive Bev on its own or in combination with a low dose (3MU) or standard dose (9MU) IFN. DCE-MRI was used to assess the changes in vascularity with the primary endpoint being, changes in transfer coefficient (Ktrans) after six weeks of treatment. I also report two retrospective imaging-based studies, using contrast-enhanced CT scans, performed to improve the methodology of response assessment for these antiangiogenic therapeutics. Here I explore the use of a) combining changes in size and arterial phase contrast enhancement measured using CT scan and b) changes in CT texture as methods of therapeutic response assessment in mRCC patients treated with TKI. Results: With the phase 2 clinical trial, we faced significant difficulty in recruitment as a result of restrictions in access to treatment in NHS, other competing studies and restrictions proposed by the DCE-MRI inclusion criteria. With slow recruitment, an unplanned analysis was performed after 21 patients were recruited. Analysis of primary endpoint showed no trend in the difference between arms with no correlation found between change in Ktrans and addition of IFN to bevacizumab. Effect size analysis performed due to the small numbers recruited failed to show any significance in the observed difference in Ktrans. Change in Ktrans and Kep may identify a group of patients likely to have PFS > 6 months, but this observation needs to evaluation in a larger sample size. Measuring size and change in arterial phase enhancement retrospectively using CT, a new criterion "modified" Choi, which prerequisite a combination of a decrease in arterial phase density by 15% and a decrease in size by 10% for response was proposed. Response assessment was measured with RECIST, Choi and modified Choi individually in 20 evaluable patients retrospectively and clinical benefit compared with Kaplan-Meier statistics and Log-Rank test. Response assessment as defined by the modified Choi criteria successfully identified patients who received clinical benefit from the treatment. Time to progression (TTP) was 448 days for the partial response and 89 days for stable disease as per the new criteria which were statistically significant with a p-value of 0.002. The second retrospective analysis explored the textural changes in enhanced CT scan. Performed in collaboration with researchers from Brighton University who developed the software algorithm used to assess changes in entropy and uniformity, 87 metastases from 39 patients with mRCC were analysed at baseline and after two cycles of TKI treatment. Textural parameters and response assessment criteria were correlated with TTP. After two cycles of TKI, the decrease in tumour entropy was 3%-45%, and increase in uniformity was 5%-21%. At a threshold change of -2% with uniformity, on a coarse scale of 2.5, the textural change was able to separate responders from non-responders. With Kaplan-Meier analysis comparing all four criteria, the percentage change in uniformity was statistically more significant than for RECIST, Choi, and Modified Choi criteria. Cox regression analysis showed that texture uniformity was an independent predictor of time to progression. Discussion: With the studies reported here, I was able to demonstrate the importance of improving the methodology in assessment of therapeutic response to targeted anti-angiogenic therapy in metastatic renal cell carcinoma. Even though the clinical trial, terminated early due to slow recruitment, did not reach its primary endpoint, changes in other vascular parameters as Kep combined with changes Ktrans showed tendency towards identifying a group of patients who derived clinical benefit of >6months with these therapies. This is particularly exciting as given the vascular stabilisation effect proposed for bevacizumab, the effusion parameter Kep may be a better tool in assessing response rather than Ktrans and warrants further assessment in a larger cohort. Modified choi criterion and textural analysis are two important methodological improvements in response assessment of cytostatic anti-angiogenic therapy. In the analyses reported here, both techniques have shown superiority over RECIST in response assessment and differentiating mRCC patients who is likely to gain clinical benefit by TKI therapy. Validation of these criteria on a larger patient cohort is important. As these criterions are assessed on standard enhanced CT scans, incorporating these criteria, especially modified choi criterion, as part of standard CT assessment could be performed and will provide a real world validation. Retrospective assessment using larger cohort of patients from previous phase 3 trials or inclusion of these parameters prospectively in phase 3 trials would also help us in evaluating these modalities further.

La séquence d’IRM de perfusion pondérée T1 après injection de Gadolinium (Gd), appelée dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) fait partie du protocole d’IRM multiparamétrique (IRM-mp) réalisée pour le bilan d’extension du cancer prostatique (CaP). Le rationnel pour l’utilisation de cette séquence est d’une part le rôle capital de la néoangiogénèse dans le développement et la dissémination du CaP et d’autre part la possibilité d’imager l’angiogénèse in vivo et de façon non invasive. L’analyse quantitative nécessite un post-traitement multi-étapes complexe, dont le principe repose sur la modélisation pharmacocinétique (PC) de la biodistrubtion du Gd. Elle permet de calculer des paramètres PC reflétant la perméabilité capillaire et/ou la perfusion. Dans le CaP, ces paramètres PC ont montré leur potentiel pour évaluer l’agressivité tumorale, le pronostic, l’efficacité d’un traitement et/ou pour déterminer la dose efficace d’une nouvelle molécule anti-angiogéniques ou antivasculaires en cours de développement. Néanmoins, ils manquent de reproductibilité, notamment du fait des différentes techniques de quantifications utilisées par les logiciels de post-traitement.Nous avons développé au sein du laboratoire un outil de quantification capable de calculer une cartographie T1(0) à partir de la méthode des angles de bascule variables, nécessaire pour convertir les courbes du signal en courbe de concentration du Gd (Ct); de déterminer la fonction d’entrée artérielle (AIF – arterial input function) dans l’artère fémorale (Indivuduelle – Ind) ou lorsque cela n’était pas possible, d’utiliser une AIF issue de la littérature, telle que celle de Weinmann (W) ou de Fritz-Hansen (FH) ; et d’utiliser deux modèles PC, celui de Tofts et celui de Tofts modifié. Le logiciel a été validé sur des données simulées et sur une petite série clinique.Nous avons ensuite étudié l’impact du choix de la fonction d’entrée artériel sur les paramètres PC et notamment sur leur capacité à distinguer le CaP du tissu sain. 38 patients avec un CaP (>0,5cc) de la zone périphérique (ZP) ont été rétrospectivement inclus. Chaque patient avait bénéficié d’une IRM-mp sur laquelle deux régions d’intérêt (RI) : une tumorale et une bénigne ont été sélectionnées en utilisant une corrélation avec des cartes histo-morphométriques obtenues après prostatectomie radicale. En utilisant trois logiciels d’analyse quantitative différents, les valeurs moyennes de Ktrans (constante de transfert), ve (fraction du volume interstitiel) and vp (fraction du volume plasmatique) dans les RI ont été calculées avec trois AIF différentes (AIF Ind, AIF de W et AIF de FH). Ktrans était le paramètre PC qui permettait de mieux distinguer le CaP du tissu sain et ses valeurs étaient significativement supérieures dans le CaP, quelque soit l’AIF ou le logiciel. L’AIF de W donnait des aires sous les courbes ROC (Receiver Operating Characteristic) significativement plus grandes que l’AIF de FH (0.002≤p≤0.045) et plus grandes ou égales à l’AIF Ind (0.014≤p≤0.9). L’AIF Ind et de FH avaient des aires sous les courbes ROC comparables (0.34≤p≤0.81). Nous avons donc montré que les valeurs de Ktrans et sa capacité à distinguer CaP du tissu sain variaient significativement avec le choix de l’AIF et que les meilleures performances étaient obtenues avec l’AIF de W. / Dynamic contrast enhanced (DCE)-MRI is a T1 weighted sequence performed before, during and after a bolus injection of a contrast agent (CA). It is included in the multi-parametric prostate MRI (mp-MRI) protocol using to assess the extent of prostate cancer (PCa). The rationale for using DCE-MRI in PCa is that on one hand angiogenesis has been shown to play a central role in the PCa development and metastasis and on the other hand that DCE-MRI is a non invasive method able to depict this angiogenesis in vivo. The quantitative analysis of DCE-MRI data is a complex and multi-step process. The principle is to use a pharmacokinetic (PK) model reflecting the theoretical distribution of the CA in a tissue to extract PK parameters that describe the perfusion and capillary permeability. These parameters are of growing interest, especially in the field of oncology, for their use in assessing the aggressiveness, the prognosis and the efficacy of anti-angiogenic or anti-vascular treatments. The potential utility of these parameters is significant; however, the parameters often lack reproducibility, particularly between different quantitative analysis software programs.Firstly, we developed a quantitative analysis software solution using the variable flip angle method to estimate the T1 mapping which is needed to convert the signal-time curves to CA concentration-time curves; using three different arterial input functions (AIF): an individual AIF (Ind) measured manually in a large artery, and two literature population average AIFs of Weinmann (W) and of Fritz-Hansen (FH); and using two PK models (Tofts and modified Tofts). The robustness of the software programs was assessed on synthetic DCE-MRI data set and on a clinical DCE-MRI data set. Secondly, we assessed the impact of the AIF selection on the PK parameters to distinguish PCa from benign tissue. 38 patients with clinically important peripheral PCa (≥0.5cc) were retrospectively included. These patients underwent 1.5T multiparametric prostate MR with PCa and benign regions of interest (ROI) selected using a visual registration with morphometric reconstruction obtained from radical prostatectomy. Using three pharmacokinetic (PK) analysis software programs, the mean Ktrans, ve and vp of ROIs were computed using three AIFs: Ind-AIF, W-AIF and FH-AIF. The Ktrans provided higher area under the receiver operating characteristic curves (AUROCC) than ve and vp. The Ktrans was significantly higher in the PCa ROIs than in the benign ROIs. AUROCCs obtained with W-AIF were significantly higher than FH-AIF (0.002≤p≤0.045) and similar to or higher than Ind-AIF (0.014≤p≤0.9). Ind-AIF and FH-AIF provided similar AUROCC (0.34≤p≤0.81).We have then demonstrated that the selection of AIF can modify the capacity of the PK parameter Ktrans to distinguish PCa from benign tissue and that W-AIF yielded a similar or higher performance than Ind-AIF and a higher performance than FH-AIF.

<b>Background:</b> Systemic chemotherapy and radiotherapy play an important role in the treatment of colorectal cancer. Tumour perfusion and oxygenation is known to influence radiosensitivity and chemosensitivity. In this thesis, I propose that the evaluation of changes in tumour perfusion using perfusion CT (pCT) and dynamic contrast-enhanced (Dce) MRI can guide the rational sequencing of drugs and radiation. <b>Methods:</b> Dce-MRI and pCT scans were incorporated into a clinical trial of hypofractionated pelvic radiotherapy and nelfinavir in 10 patients with rectal cancer. Toxicity and tissue biomarkers (tumour cell density, microvessel density, CAIX, HIF1-alpha, phospho-Akt and phospho-PRAS40) were evaluated. pCT liver scans were incorporated into an imaging study in patients with colorectal liver metastases randomised to receive either oxaliplatin/ 5FU chemotherapy or oxaliplatin/ 5FU chemotherapy plus selective internal radiotherapy. <b>Results:</b> After 7 days of nelfinavir concurrent with hypo-fractionated pelvic radiotherapy, there was a mean 42&percnt; increase in median K^trans (P=0.03, paired t test) on Dce-MRI and a median 30&percnt; increase in mean blood flow on pCT (P=0.028, Wilcoxon Rank Sum), although no statistically significant changes in perfusion parameters were demonstrated after 7 days of nelfinavir prior to radiotherapy. The feasibility of evaluating tumour cell density in rectal biopsies before and after radiotherapy and a radiosensitising drug as an early endpoint of response was demonstrated. In patients with colorectal liver metastases who received oxaliplatin and modified de Gramont chemotherapy alone, after 4 cycles of chemotherapy, a 28&percnt; decrease in the mean hepatic arterial fraction was observed (P=0.018, paired t test). Between pCT scans 2 days before SIRT and 39-47 days following SIRT and continued 2-weekly chemotherapy, there was a mean 62&percnt; (P=0.009) reduction in Blood Flow and 61&percnt; (P=0.006) reduction in Blood Volume (paired t test). <b>Conclusions</b> This research does not support the hypothesis that nelfinavir before radiotherapy improves blood flow to human rectal cancer. Increases in rectal tumour perfusion during radiotherapy and concurrent nelfinavir are likely to be primarily explained by the acute biological effects of radiation. Four or more cycles of oxaliplatin and modified de Gramont chemotherapy may result in changes in tumour perfusion of colorectal liver metastases which would be detrimental to subsequent radiotherapy. Selective internal radiotherapy resulted in substantial reductions in tumour perfusion 39-47 days after the treatment. Perfusion imaging can be used to detect changes in tumour perfusion in response to radiotherapy and systemic therapy which have implications for the sequencing of therapies.

No description available.

Perfusion magnetic resonance imaging is modern diagnostic method used mainly in oncology. In this method, contrast agent is injected to the subject and then is continuously monitored the progress of its concentration in the affected area in time. Correct determination of the arterial input function (AIF) is very important for perfusion analysis. One possibility is to model AIF by multichannel blind deconvolution but the estimated AIF is necessary to be scaled. This master´s thesis is focused on description of scaling methods and their influence on perfussion parameters in dependence on used model of AIF in different tissues.

L’insuffisance placentaire par défaut de vascularisation est une pathologie fréquente de la grossesse, de diagnostic difficile, avec des complications potentiellement graves (retard de croissance intra utérin, prééclampsie). L’objectif de ce travail de Thèse a été de développer l’IRM fonctionnelle multiparamétrique pour l’exploration du placenta à 4.7 T chez la rate gestante. Matériel et méthode : L’IRM de diffusion (SE- EPI DWI) avec analyse IVIM et l’IRM dynamique avec injection de gadolinium (DCE) et haute résolution temporelle (< 1s) ont été développées puis étudiées sur un modèle murin contrôlé d’hypoperfusion placentaire par ligature du pédicule vasculaire utérin gauche au 17ème jour de gestation. Les paramètres obtenus sur les placentas hypoperfusés de la corne gauche ligaturée étaient comparés à ceux des placentas normaux de la corne droite. L’effet de l’hyperoxygénation maternelle était étudié en diffusion. Résultats : Ont été étudiés 73 placentas, dont 23 pathologiques (n= 10 rates) en diffusion et 53 placentas, dont 11 pathologiques (n=12 rates) en DCE. Les paramètres significativement diminués du côté hypoperfusé étaient le coefficient apparent de diffusion (ADC), la fraction de perfusion (f) en diffusion et le flux sanguin maternel (F) en DCE. Sous hyperoxygénation maternelle, l’ADC et le coefficient de diffusion (D) augmentaient et f diminuait. Les paramètres obtenus en diffusion et en DCE n’étaient pas nettement corrélés entre eux. Conclusion : Un outil d’IRM fonctionnelle placentaire multiparamétrique a été développé à 4.7 T chez la rate gestante. La DWI comme la DCE apparaissent complémentaires pour le diagnostic d’hypoperfusion placentaire. / Placental insufficiency caused by deficient vascularization is common during pregnancy, difficult to diagnose and can lead to severe materno-fetal complications (intrauterine growth restriction, preeclampsia). The aim of this work was to develop multi-parametric functional magnetic resonance imaging (MRI) to assess the placenta at 4.7 T on a murine model. Materials and methods : Diffusion-weighted imaging (SE-EPI-DWI) with the intravoxel incoherent motion (IVIM) analysis and dynamic contrast enhanced MRI (DCE) with a high-time resolution (<1 s) were developed and evaluated on a controlled rat model of reduced placental perfusion, achieved by ligation of the left uterine vascular pedicle on the 17th embryonic day. Parameters from the placentas in the left ligated horn were compared to those from the normal placentas in the non ligated horn. The effect of maternal hyperoxygenation on placental microvascularization was studied with DWI.Results: For DWI, 73 placentas were examined, 23 from the ligated side (n=10 rats). For DCE, 53 placentas were analysed, 11 from the ligated side (n=12 rats). In the uterine horn with reduced perfusion, the apparent diffusion coefficient (ADC), the perfusion fraction (f) obtained with DWI and the placental blood flow (F) obtained with DCE were significantly decreased. Under maternal hyperoxygenation, ADC and the diffusion coefficient (D) increased whereas f decreased. DWI and DCE parameters were not significantly correlated with each other. Conclusion: Multi-parametric MRI has been developed for murine placental analysis at 4.7T. DWI and DCE are complementary tools for the diagnosis of reduced placental perfusion.

L’échographie dynamique de contraste (DCE-US) est actuellement proposée comme technique d’imagerie fonctionnelle permettant d’évaluer les nouvelles thérapies anti-angiogéniques. Dans ce contexte, L'UPRES EA 4040, Université Paris-Sud 11, et le service d'Echographie de l'Institut Gustave Roussy ont développé une méthodologie permettant de calculer automatiquement, à partir de la courbe de prise de contraste moyenne obtenue dans la tumeur après injection en bolus d’un agent de contraste, un ensemble de paramètres semi-quantitatifs. Actuellement, l’état hémodynamique du patient ou encore les conditions d’injection du produit de contraste ne sont pas pris en compte dans le calcul de ces paramètres à l’inverse d’autres modalités (imagerie par résonance magnétique dynamique de contraste ou scanner de perfusion). L’objectif de cette thèse était donc d’étendre la méthode de déconvolution utilisée en routine dans les autres modalités d’imagerie à l’échographie de contraste. Celle-ci permet de s’affranchir des conditions citées précédemment en déconvoluant la courbe de prise de contraste issue de la tumeur par la fonction d’entrée artérielle, donnant ainsi accès aux paramètres quantitatifs flux sanguin, volume sanguin et temps de transit moyen. Mon travail de recherche s’est alors articulé autour de trois axes. Le premier visait à développer la méthode de quantification par déconvolution dédiée à l’échographie de contraste, avec l’élaboration d’un outil méthodologique suivie de l’évaluation de son apport sur la variabilité des paramètres de la microvascularisation. Des évaluations comparatives de variabilité intra-opérateur ont alors mis en évidence une diminution drastique des coefficients de variation des paramètres de la microvascularisation de 30% à 13% avec la méthode de déconvolution. Le deuxième axe était centré sur l’étude des sources de variabilité influençant les paramètres de la microvascularisation portant à la fois sur les conditions expérimentales et sur les conditions physiologiques de la tumeur. Enfin, le dernier axe a reposé sur une étude rétrospective menée sur 12 patients pour lesquels nous avons évalué l’intérêt de la déconvolution en comparant l’évolution des paramètres quantitatifs et semi-quantitatifs de la microvascularisation en fonction des réponses des tumeurs obtenues par les critères RECIST à partir d’un scan effectué à 2 mois. Cette méthodologie est prometteuse et peut permettre à terme une évaluation plus robuste et précoce des thérapies anti-angiogéniques que les méthodologies actuellement utilisées en routine dans le cadre des examens DCE-US. / Dynamic contrast-enhanced ultrasonography (DCE-US) is currently used as a functional imaging technique for evaluating anti-angiogenic therapies. A mathematical model has been developed by the UPRES EA 4040, Paris-Sud university and the Gustave Roussy Institute to evaluate semi-quantitative microvascularization parameters directly from time-intensity curves. But DCE-US evaluation of such parameters does not yet take into account physiological variations of the patient or even the way the contrast agent is injected as opposed to other functional modalities (dynamic magnetic resonance imaging or perfusion scintigraphy). The aim of my PhD was to develop a deconvolution process dedicated to the DCE-US imaging, which is currently used as a routine method in other imaging modalities. Such a process would allow access to quantitatively-defined microvascularization parameters since it would provide absolute evaluation of the tumor blood flow, the tumor blood volume and the mean transit time. This PhD has been led according to three main goals. First, we developed a deconvolution method involving the creation of a quantification tool and validation through studies of the microvascularization parameter variability. Evaluation and comparison of intra-operator variabilities demonstrated a decrease in the coefficients of variation from 30% to 13% when microvascularization parameters were extracted using the deconvolution process. Secondly, we evaluated sources of variation that influence microvascularization parameters concerning both the experimental conditions and the physiological conditions of the tumor. Finally, we performed a retrospective study involving 12 patients for whom we evaluated the benefit of the deconvolution process: we compared the evolution of the quantitative and semi-quantitative microvascularization parameters based on tumor responses evaluated by the RECIST criteria obtained through a scan performed after 2 months. Deconvolution is a promising process that may allow an earlier, more robust evaluation of anti-angiogenic treatments than the DCE-US method in current clinical use.

Trois aspects principaux de l'imagerie fonctionnelle corps entier dans les hémopathies lymphoïdes ont été étudiés dans ma thèse. Nous avons d'abord démontré en étudiant 92 patients avec un lymphome B à grandes cellules que 14 patients (15%) considérés positifs sur l'analyse visuelle du FDG-TEP après deux cycles de chimiothérapie, auraient pu être reclassés comme des bons répondeurs si le pourcentage de réduction du SUVmax avait été mesuré. Dans un sous groupe de 80 patients, une deuxième étude a permis de montrer qu'après 4 cycles, l'analyse visuelle et l'analyse semi-quantitative SUV étaient équivalentes. Nous avons ensuite développé un protocole d'IRM fonctionnelle corps entier, utilisant une injection dynamique de Gadolinium et 5 stations d'acquisition. Cela a permis de mesurer les courbes signal-temps du rehaussement de la moelle osseuse et des lésions focales. Notre étude a permis d'optimiser un protocole d'imagerie dynamique corps entier après injection de Gadolinium, et de montrer que nous avions pu explorer avec succès 21 patients présentant un myélome multiple sous traitement, nous avons montré que cette nouvelle méthode d'IRM fonctionnelle corps entier avec injection de Gadolinium pouvait être utilisée pour évaluer la réponse du traitement. De plus, cette technique a aidé à détecter les lésions résiduelles actives de myélome après traitement alors qu'aucun signe clinique ou une immunoglobine monoclonale minime n'était présent. Le troisième aspect a été d'optimiser un protocole d'IRM fonctionnelle corps entier utilisant l'imagerie de diffusion avec asservissement respiratoire. Le but est de pouvoir mesurer le coefficient de diffusion apprent des lésions disséminées. L'étude pilote a été réalisée chez 15 patients avec un lymphome B à grandes cellules avant traitement. Nous avons aussi pu montrer les changements d'ADC après 4 cycles de chimiothérapie en considérant l'imagerie FDG-TEP/scanner comme imagerie de référence / Three components regarding whole-body functional imaging in lymphoid malignancies have been studies in this thesis. We first demonstrated retrospectively in a series of 92 patients with diffuse large B-cell lymphoma (DLBCL) that 14 patients (15%) considered as positive on visual analysis on FDG-PET after only 2 cycles of chemotherapy could have been correctly re-classified as good responders by measuring the percentage reduction of maximum standardized uptake value (SUVmax); in a subgroup of 80 patients, SUV-based assessment was equivalent to visual analysis at 4 cycles for patient outcome prediction. We secondly developed a whole-body 5-station dynamic contrast- enhanced MR protocol and time-signal intensity curves for the bone marrow and the focal lesions were successfully obtaines in 21 patients with plasma cell disorders included in the feasibility study; later in a pilot prospective study with 30 patients with multiple myeloma who received systemic therapy, we showed that this novel whole-body functional MR technique can be used to assess treatment response and helps to delect residual active disease after completion of therapy when clinically no or only minimum monoclonal protein can be identified. We thirdly optimized a whole-body diffusion-weighted MR protocol with respiratory gating in order to determine apparent diffusion coefficient (ADC) value on a whole-body scale. Pilot study was performed in 15 patients with DLBCL for both staging and response assessment at 4 cycles of chemotherapy, with FDG PET/CT as the standard of reference

Applying mathematical models to dynamic contrast enhanced MRI (DCE MRI) data to perform quantitative tracer kinetic analysis enables the estimation of tissue characteristics such as vascular permeability and the fractional volume of plasma in a tissue. However, it is unclear to what extent modeling assumptions, particularly regarding water exchange between tissue compartments, impacts parameter estimates derived from clinical DCE MRI data. In this work, a new model is developed which includes water exchange effects, termed the water exchange modified two compartment exchange model (WX-2CXM). Two boundaries of this model (the fast and no exchange limits) were used to analyse a clinical DCE MRI bladder cancer dataset. Comparisons with DCE CT, which is not affected by water exchange, suggested that water exchange may have affected estimates of vp, the fractional volume of plasma. Further investigation and simulations led to the development of a DCE MRI protocol which was sensitised to water exchange, in order to further evaluate the water exchange effects found in the bladder cancer dataset. This protocol was tested by imaging the parotid glands in eight healthy volunteers, and confirmed evidence of water exchange effects on vp, as well as flow Fp and the fractional volume of extravascular extracellular space ve. This protocol also enabled preliminary estimates of the water residence times in parotid tissue, however, these estimates had a large variability and require further validation. The work presented in this thesis suggests that, although water exchange effects do not have a large effect on clinical data, the effect is measurable, and may lead to the ability to estimate of tissue water residence times. Results do not support a change in the current practise of neglecting water exchange effects in clinical DCEMRI acquisitions.